Table 1. Correlation between SNHG9 expression and clinicopathological characteristics in prostate cancer.
| Characters | Level | Low expression of SNHG9 | High expression of SNHG9 | P | Test |
|---|---|---|---|---|---|
| n | 248 | 247 | |||
| T stage, n (%) | T2 | 105 (43.4) | 82 (33.3) | 0.064 | Exact |
| T3 | 133 (55.0) | 158 (64.2) | |||
| T4 | 4 (1.7) | 6 (2.4) | |||
| N stage, n (%) | N0 | 185 (88.9) | 159 (74.3) | <0.001 | |
| N1 | 23 (11.1) | 55 (25.7) | |||
| M stage, n (%) | M0 | 222 (99.6) | 231 (99.1) | 1.000 | Exact |
| M1 | 1 (0.4) | 2 (0.9) | |||
| Gleason score, n (%) | 10 | 3 (1.2) | 1 (0.4) | 0.002 | Exact |
| 6 | 20 (8.1) | 25 (10.1) | |||
| 7 | 144 (58.1) | 102 (41.3) | |||
| 8 | 27 (10.9) | 36 (14.6) | |||
| 9 | 54 (21.8) | 83 (33.6) | |||
| Primary therapy outcome, n (%) | CR | 188 (85.1) | 149 (70.0) | 0.001 | |
| PD | 13 (5.9) | 15 (7.0) | |||
| PR | 12 (5.4) | 28 (13.1) | |||
| SD | 8 (3.6) | 21 (9.9) | |||
| Residual tumor, n (%) | R0 | 173 (74.6) | 141 (60.5) | <0.001 | Exact |
| R1 | 55 (23.7) | 91 (39.1) | |||
| R2 | 4 (1.7) | 1 (0.4) | |||
| Race, n (%) | Asian | 7 (2.9) | 5 (2.1) | 0.211 | |
| Black or African American | 34 (14.0) | 22 (9.2) | |||
| White | 201 (83.1) | 211 (88.7) | |||
| Zone of origin, n (%) | Central zone | 3 (3.2) | 1 (0.6) | 0.363 | Exact |
| Overlapping/multiple zones | 44 (46.8) | 82 (45.6) | |||
| Peripheral zone | 44 (46.8) | 92 (51.1) | |||
| Transition zone | 3 (3.2) | 5 (2.8) | |||
| TP53 status, n (%) | Mut | 21 (8.5) | 35 (14.2) | 0.065 | |
| WT | 225 (91.5) | 211 (85.8) | |||
| Age [median (IQR)] | 61.00 [56.00, 66.00] | 62.00 [56.00, 66.00] | 0.443 | Nonnorm | |
| PSA (ng/mL) [median (IQR)] | 0.10 [0.03, 0.11] | 0.10 [0.01, 0.12] | 0.007 | Nonnorm |
CR, complete response; PD, progressive disease; SD, stable disease; PR, partial response; PSA, prostate specific antigen.